MSN 611 Final Exam Questions With Correct
Answers
Eosinophils, |neutrophils, |and |T |cells |contain |the |type |of |histamine |receptors |referred |to |as |- |
CORRECT |ANSWER✔✔-H4
Second |generation |antihistamine |that |cannot |be |removed |by |hemodialysis |- |CORRECT |
ANSWER✔✔-Cetirizine
How |is |enterobiasis |diagnosed? |- |CORRECT |ANSWER✔✔-Perianal |swab |examination |for |eggs
Treatment |modalities |of |tuberculosis |- |CORRECT |ANSWER✔✔-directly |observed |therapy |to |
ensure |adherence |to |drug |regimen |(if |the |regimen |is |less |than |daily); |if |patient |has |a |decline |
provider |should |ensure |no |drug |resistance, |proper |compliance, |and |no |interactions
According |to |the |universal |prescribing |alerts |for |ahminoglycosides |extended |use |increases |risk |
for |infection |by |which |of |the |pathogens |- |CORRECT |ANSWER✔✔-C. |difficile
Mode |of |administration |of |dactinomycin |- |CORRECT |ANSWER✔✔-dactinomycin |is |a |vesicant |
that |should |only |be |administered |intravenously |to |prevent |extravasation
Which |of |the |following |is |an |FDA |approved |indication |for |m |methotrexate? |- |CORRECT |
ANSWER✔✔-Breast |cancer, |meningeal |leukemia, |& |trophoblastic |neoplasms
Synthetic |muscarinic |receptor |antagonist |that |possess |M3 |receptor |selectivity |- |CORRECT |
ANSWER✔✔-The |synthetic |derivatives |possessing |some |degree |of |M3 |receptor |selectivity |
include |the |newer |agents |darifenacin |and |solifenacin
, Autonomic |agents |associated |stimulation |of |insulin |production, |increase |glycogenolysis |in |the |
liver, |and |complicate |the |management |of |diabetes |mellitus? |- |CORRECT |ANSWER✔✔-
Sympathomimentic |autonomic |agents |may |also |stimulate |insulin |production, |increase |
glycogenolysis |in |the |liver |and |complicate |the |management |of |diabetes |mellitus
Most |commonly |used |therapy |for |iron |deficiency |anemia |- |CORRECT |ANSWER✔✔-ferrous |
sulfate
Fatalities |have |occurred |with |the |test |dose |of |which |drug |- |CORRECT |ANSWER✔✔-iron |
dextran
Antilipemic |agent |that |targets |triglycerides |- |CORRECT |ANSWER✔✔-Fibrates
Mechanism |of |action |of |calcium |channel |blocking |agents |- |CORRECT |ANSWER✔✔-act |on |
calcium |channels |in |the |large |vessels |to |produce |vasodilation |and |subsequent |reduction |in |
blood |pressure
Hypotensive |agent |FDA |approved |for |treatment |of |ADHD |- |CORRECT |ANSWER✔✔-Extended |
release |guanfacine
When |prescribing |benzodiazepines, |only |lorazepam, |oxazepam, |or |temazepam |should |be |
considered |for |which |patients |- |CORRECT |ANSWER✔✔-hepatic |impairment
Lithium |is |used |as |a |treatment |for: |- |CORRECT |ANSWER✔✔-Mania, |or |depressive |symptoms |in
|bipolar |disorder
An |important |consideration |when |administering |total |parenteral |nutrition |peripherally |is |that:
|- |CORRECT |ANSWER✔✔-it |should |have |a |lower |osmolality |than |for |a |central |line
Answers
Eosinophils, |neutrophils, |and |T |cells |contain |the |type |of |histamine |receptors |referred |to |as |- |
CORRECT |ANSWER✔✔-H4
Second |generation |antihistamine |that |cannot |be |removed |by |hemodialysis |- |CORRECT |
ANSWER✔✔-Cetirizine
How |is |enterobiasis |diagnosed? |- |CORRECT |ANSWER✔✔-Perianal |swab |examination |for |eggs
Treatment |modalities |of |tuberculosis |- |CORRECT |ANSWER✔✔-directly |observed |therapy |to |
ensure |adherence |to |drug |regimen |(if |the |regimen |is |less |than |daily); |if |patient |has |a |decline |
provider |should |ensure |no |drug |resistance, |proper |compliance, |and |no |interactions
According |to |the |universal |prescribing |alerts |for |ahminoglycosides |extended |use |increases |risk |
for |infection |by |which |of |the |pathogens |- |CORRECT |ANSWER✔✔-C. |difficile
Mode |of |administration |of |dactinomycin |- |CORRECT |ANSWER✔✔-dactinomycin |is |a |vesicant |
that |should |only |be |administered |intravenously |to |prevent |extravasation
Which |of |the |following |is |an |FDA |approved |indication |for |m |methotrexate? |- |CORRECT |
ANSWER✔✔-Breast |cancer, |meningeal |leukemia, |& |trophoblastic |neoplasms
Synthetic |muscarinic |receptor |antagonist |that |possess |M3 |receptor |selectivity |- |CORRECT |
ANSWER✔✔-The |synthetic |derivatives |possessing |some |degree |of |M3 |receptor |selectivity |
include |the |newer |agents |darifenacin |and |solifenacin
, Autonomic |agents |associated |stimulation |of |insulin |production, |increase |glycogenolysis |in |the |
liver, |and |complicate |the |management |of |diabetes |mellitus? |- |CORRECT |ANSWER✔✔-
Sympathomimentic |autonomic |agents |may |also |stimulate |insulin |production, |increase |
glycogenolysis |in |the |liver |and |complicate |the |management |of |diabetes |mellitus
Most |commonly |used |therapy |for |iron |deficiency |anemia |- |CORRECT |ANSWER✔✔-ferrous |
sulfate
Fatalities |have |occurred |with |the |test |dose |of |which |drug |- |CORRECT |ANSWER✔✔-iron |
dextran
Antilipemic |agent |that |targets |triglycerides |- |CORRECT |ANSWER✔✔-Fibrates
Mechanism |of |action |of |calcium |channel |blocking |agents |- |CORRECT |ANSWER✔✔-act |on |
calcium |channels |in |the |large |vessels |to |produce |vasodilation |and |subsequent |reduction |in |
blood |pressure
Hypotensive |agent |FDA |approved |for |treatment |of |ADHD |- |CORRECT |ANSWER✔✔-Extended |
release |guanfacine
When |prescribing |benzodiazepines, |only |lorazepam, |oxazepam, |or |temazepam |should |be |
considered |for |which |patients |- |CORRECT |ANSWER✔✔-hepatic |impairment
Lithium |is |used |as |a |treatment |for: |- |CORRECT |ANSWER✔✔-Mania, |or |depressive |symptoms |in
|bipolar |disorder
An |important |consideration |when |administering |total |parenteral |nutrition |peripherally |is |that:
|- |CORRECT |ANSWER✔✔-it |should |have |a |lower |osmolality |than |for |a |central |line
